Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology | Neurology
Disease Category: Gliomas
Location: United States, WA
A Phase 2 Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain
The purpose of this study is to determine the safety and usefulness of 5-aminolevulinic acid (ALA) for identifying your tumor during surgery. When your doctor removes the tumor from your brain, it is important that they remove all of the tumor and not remove parts of normal brain. Sometimes this can be difficult because the tumor can look like normal brain. In some brain tumors ALA can make the tumors glow red under ultraviolet light (a "black light"). This may make it easier for your doctor to identify and remove more tumor tissue.
Patient Inclusion Criteria:
Patient Exclusion Criteria:
CW ID: 183317
Date Last Changed:
July 16, 2013
Christine Goetz, BA; CCRCMultiCare Health System314 Martin Luther King, Jr. Way, Suite 402Tacoma, WA 98405Phone: 253-403-7193
MultiCare Health System
If you would like to learn more about participating in this research study, please email the trial contact using the form below.
We value your privacy and your information will only be used by the research center to contact
you regarding this study.
DISCLAIMER: CenterWatch does not conduct clinical research.
CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies,
contract research organizations, clinical research sites and other interested parties. This information
is designed to help patients find clinical trials of interest and contact the research centers
conducting the trials.
Copyright © 1995-2016 CenterWatch.